Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes

Aims To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl‐peptidase‐4 inhibitors [DPP‐4s] or sulfonylureas. Methods We identified Medicare beneficiaries aged >65 years who initiated treatment with pioglitazone (N ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2018-01, Vol.20 (1), p.129-140
Hauptverfasser:	Garry, Elizabeth M., Buse, John B., Lund, Jennifer L., Pate, Virginia, Stürmer, Til
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Aging antidiabetic drug Antidiabetics Bladder cancer Cancer Cohort Studies database research Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-peptidase IV Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use DPP‐IV inhibitor Drug Prescriptions Electronic Health Records Epidemiology Female Follow-Up Studies Health risk assessment Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incidence Latency Male Medicare Peptidase Pharmacovigilance pharmaco‐epidemiology Pioglitazone Proportional Hazards Models Risk Sensitivity analysis Sulfonylurea Compounds - adverse effects Sulfonylurea Compounds - therapeutic use thiazolidinediones Thiazolidinediones - adverse effects Thiazolidinediones - therapeutic use United States - epidemiology Urinary bladder Urinary Bladder Neoplasms - chemically induced Urinary Bladder Neoplasms - complications Urinary Bladder Neoplasms - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!